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Abstract: Background: Obstructive sleep apnea syndrome (OSAS) is associated with a variety of 
inflammatory factors. Specifically, proinflammatory cytokines appear to be associated with the 
pathogenesis of OSAS. Methods: For the present meta-analysis and meta-regression on serum and 
plasma tumor necrosis factor alpha (TNF-α) levels in individuals with and without OSAS, we 
performed a systematic search without any restrictions of the PubMed/Medline, Scopus, Cochrane 
Library, and Web of Science databases to find relevant articles published up to February 1, 2020. 
Results: Fifty-five (adults: 29 studies on serum and 17 studies on plasma; children: 4 studies on 
serum and 5 studies on plasma) were included and analyzed. Always compared to age-matched 
healthy controls, the pooled MDs were as follows: adults, serum: 10.22 pg/mL (95% CI = 8.86, 
11.58; p < 0.00001); adults, plasma: 5.90 pg/mL (95% CI = 4.00, 7.80; p < 0.00001); children, serum: 
0.21 pg/mL (95% CI = 0.05, 0.37; p = 0.01); children, plasma: 5.90 pg/mL (95% CI = 4.00, 7.80; p < 
0.00001). Conclusions: Compared to healthy and age-matched controls, adult individuals with 
OSAS had significantly higher serum/plasma TNF-α levels. For children with OSAS, significantly 
higher levels were observed for TNF-α in serum but not in plasma. 
Keywords: obstructive sleep apnea syndrome; cytokine; tumor necrosis factor alpha; serum; 
plasma; meta-analysis; meta-regression 
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1. Introduction 
Obstructive sleep apnea syndrome (OSAS) is a common sleep-related breathing disorder. It is 
estimated that 4% of both female and male adults suffer from OSAS [1]. Specifically, about 2% 
middle-aged individuals (30–60 years) suffer from OSAS, and prevalence rates increased by 30% to 
50% in adults with overweight and obesity [2,3]. Typically, in individuals with OSAS, the repetitive 
obstruction of the upper airway during sleep leads to hypoxemia, arousals, intermittent snoring, 
episodes of complete apnea, and to increased daytime sleepiness as a result of non-restoring sleep 
[4]. To define OSAS, both objective and subjective measurements are applied: While self-rating 
questionnaires such as the STOP-Bang [5,6] allow a rough screening, polysomnography is the gold 
standard: OSAS are defined as the Apnea–Hypopnea Index (AHI) > 5 events per hour [7]. 
People with objectively assessed OSAS are at increased risk to suffer from atherogenesis [8], 
vascular dysfunction [9], congestive heart failure, hypertension, atrial fibrillation, nocturnal 
arrhythmias, stroke, pulmonary hypertension, and metabolic syndrome [10,11]. 
As regards the immune system, the tumor necrosis factor alpha (TNF-α) is a common cytokine 
secreted by adipocytes and the mononuclear-macrophage system [12], which regulates the immune 
system, induces inflammation, and participates in the regulation of fat metabolism [13]. More 
specifically, several inflammatory cells secrete proinflammatory cytokines such as TNF-α. Increased 
TNF-α concentrations can cause inflammatory responses such as neutrophil recruitment, tissue 
destruction, neovascularization [14], oxidative stress, systemic inflammation, autonomic nervous 
system dysfunction, atherosclerosis, and aging [15]. Further, highly increased TNF-α concentrations 
appear to be causally associated with the pathogenesis of diseases such as metabolic diseases, 
cardiovascular diseases, and OSAS [16]. Further, higher TNF-α concentrations were observed in 
individuals with OSAS, compared to healthy controls. In 2013, Nadeem et al. [17] showed in their 
meta-analysis of 15 case-control studies that compared to controls, individuals with OSAS had 
significantly higher TNF-α concentrations. Similarly, in 2015, Wang et al. [18] also reported in their 
meta-analysis that compared to healthy controls, individuals with OSAS had significantly higher 
serum TNF-α concentrations. With the present meta-analysis, we expand upon the previous two 
meta-analyses in that we focused on (a) both on serum and on plasma TNF-α, (b) on samples with 
adults and children with OSAS, and in that (c) we performed a meta-regression, and (d) we ran sub-
group analyses. 
2. Materials and Methods 
The meta-analysis was performed in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [19]. 
2.1. Search Strategy 
One of the authors (M. Sadeghi) systematically searched four databases, namely 
PubMed/Medline, Scopus, Cochrane Library, and Web of Science, for articles published in English 
up to 1 February 2020, with no restrictions, and with the following expressions: “sleep apnea” or 
“OSA” or “obstructive sleep apnea” or “obstructive sleep apnea syndrome” or “OSAS“, with “TNF-
alpha” or “TNF-α” or “TNF” or “tumor necrosis factor alpha”; and with “blood” or “plasma” or 
“serum”. We also manually inspected the reference lists of the articles (original and review articles) 
for publications related to our topic. 
2.2. Eligibility Criteria 
Inclusion criteria were as follows: (1) studies evaluating the association between plasma or 
serum TNF-α levels and OSAS with case-control design without age (≥18 years as adults and <18 
years as children), sex or BMI restrictions; (2) OSAS was defined as AHI > 5 events/h diagnosed by 
polysomnography; (3) participants with OSAS and controls had no other systematic diseases such 
as diabetes, asthma, neurological disorders such as multiple sclerosis, neurodegenerative disorders 
such as Alzheimer’s disease, or oral diseases; (4) studies reporting pretreatment morning serum 
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and/or plasma levels of TNF-α (around 6:00–10:00 a.m.); (5) studies reporting sufficient data to 
compute the MD and 95% confidence interval (CI) in participants with OSAS and controls; (6) 
studies with more than 10 cases included as individuals with OSAS and controls. 
Exclusion criteria were: (1) studies with irrelevant or insufficient data or without clinical data; 
(2) Letter to the editors, review articles, conference papers, meeting abstracts, and book chapters; (3) 
studies without a control group; (4) studies reporting controls with AHI > 5 events/h; (5) studies 
with overlapped data with other studies; (6) studies without reporting cut-off AHI values for OSAS; 
(7) studies mixing pediatric and adult participants. 
2.3. Study Selection 
Two authors (M.M.I. and M.E.) read independently the titles and abstracts of the retrieved 
studies. They then selected the relevant studies, while another author (M.S.) retrieved the full-texts 
of the articles and excluded several full-texts based on the exclusion criteria mentioned above. If 
two studies had overlapped data, we selected the study with the most recent publication year. 
2.4. Data Extraction 
Two authors (S.B. and M.S.) independently extracted the data from each study included in the 
meta-analysis. If there was a disagreement between the two authors, the third author (M.M.I.) 
helped to find a final decision. The data extracted for the meta-analysis included basic information 
including the first author, publication year, country of study, ethnicity of subjects in each study, 
age, BMI, and AHI of both groups, and mean and standard deviation (SD) of TNF-α levels in 
plasma and serum. Since some studies considered patients with mild OSAS (AHI: 1–5 events/h) as a 
control group condition, and since we had to use this protocol for other studies, reporting the 
quality of studies as for usual case-control studies did not seem to be reasonable. 
2.5. Quality Assessment 
One author (M.S) evaluated the quality of the studies included in the meta-analysis using the 
Newcastle-Ottawa Scale (NOS) with a total score of nine for each study [20]. 
2.6. Statistical Analyses 
The data were analyzed by one author. Review Manager 5.3 software (RevMan 5.3, (RevMan 
5.3, The Cochrane Collaboration, Oxford, UK) was used to calculate the crude MD and 95% CI, 
which evaluated the significance of the pooled MD by Z-test. Heterogeneity across the studies was 
evaluated using both Cochran Q [21] and I2 metrics with scores ranging from 0% to 100% [22]. In 
addition, when p-value <0.1 and I2 > 50% showed a statistically significant heterogeneity, the 
analysis was performed by the random-effect model to evaluate the pooled ORs and CI values. 
Otherwise, we used the fixed-effect model. The weight (%) represents the effect of an individual 
study on the pooled results obtained. In general, the larger the sample size and the narrower CI are, 
the higher is the percentage of weight. 
The results of the Begg’s and Egger’s tests were analyzed by the Comprehensive Meta-
Analysis version 2.0 software (CMA 2.0). The Begg’s funnel plot shows the standard error (SE) of 
the log (MD), and the precision of each study is plotted against its log (MD) [23]. In addition, the 
Egger’s test shows the linear regression between the precision of the studies and the standardized 
effect [24]. 
Subgroup analyses were performed based on ethnicity, AHI, BMI, and number of participants. 
The sensitivity analyses, namely the “cumulative analysis” and “one study removed”, were applied 
to estimate the consistency/stability of the results. If the p-value (two-tailed) was less than 0.05, then 
there was a statistically significant difference. The meta-regression is a quantitative method used in 
meta-analyses to estimate the impact of moderator variables on study effect size. The trim-and-fill 
method was used to estimate potentially missing studies due to publication bias in the funnel plot 
and adjusting the overall effect estimate [25]. 
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Some studies reported the values of TNF-α in standard errors (SE); SEs were transformed into 
standard deviation (SD) (SE = SD/√N; N = number of individuals). Some studies reported median 
and interquartile values, which were transformed into mean and SD [26]. The serum and plasma 
TNF-α levels were reported in picograms per milliliter (pg/mL). Participants with BMI >30 kg/m2 
were considered obese [27]. 
3. Results 
3.1. Search Strategies 
The flow chart (Figure 1) sets out the selection process. The search databases yielded 912 
articles; of these, 117 full-texts met eligibility criteria after removing duplicates and irrelevant 
studies. Next, 62 articles were removed with reasons (two were animal studies, three were meta-
analyses, six reported polymorphisms of TNF-alpha, twenty-seven either had no control or control 
group was selected as AHI > 5, five were reviews, two had less than ten cases included in both 
groups, one reported high sensitivity TNF alpha, four had no sufficient data, one had duplicate data 
with another study, three showed production of TNF alpha by cells, two did not show cut-off of 
AHI for OSAS, one was the letter to editor, one mixed adults and pediatric samples, one had 
controls with recurrent tonsillar infection, one had controls with bronchial asthma, one had controls 
with diabetes, one had no relevant data). This left 55 studies to be analyzed in the meta-analysis 
[14,16,28–80]. 
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Figure 1. Flowchart of the study selection. 
3.2. Characteristics of Studies 
Table 1 presents the characteristics of the 55 studies included in the meta-analysis. Forty-six 
studies [16,28–36,38–41,43–52,54,56–65,67–72,75,76,78–80] reported serum or plasma TNF-α 
concentrations in adults, and nine studies [14,37,42,53,55,66,73,74,77] reported serum or plasma 
TNF-α concentrations in children and adolescents. Among adult participants, eighteen studies were 
performed with Caucasians [31,34,36,39–41,46–49,59,61,63,65,68,69,75,80], nineteen sampled Asians 
[16,29,32,33,35,43,45,52,54,58,60,62,64,67,71,72,76,78,79], and nine samples mixed 
[28,30,38,44,50,51,56,57,70] ethnicities. For studies with adult samples, 29 out of 46 studies reported 
serum TNF-α concentrations [16,31–36,38,40,41,45,46,48,50–52,56,60,61,63–65,67,68,70,76,78–80] and 
17 reported plasma TNF-α concentrations [28–30,39,43,44,47,49,54,57–59,62,69,71,72,75].
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Table 1. Characteristics of studies included in the meta-analysis (n = 55). 
First Author, Year Country Ethnicity No. of OSAS/Control 
OSAS Patients Controls 
Sample 
Age (Years) BMI (kg/m2) AHI (Events/h) Age (Years) BMI (kg/m2) AHI (Events/h) 
ADULTS 
Vgontzas, 1997 [28] USA Mixed 12/10 40.9 ± 2.2 40.5 ± 3.2 63.7 ± 10.3 24.1 ± 0.8 24.6 ± 0.7 0 ± 0 Plasma 
Huiguo, 2000 [29] China Asian 22/16 47.4 ± 13.6 27.6 ± 3.3 44.0 ± 21.0 47.6 ± 14.7 23.1 ± 3 4.29 ± 2.16 Plasma 
Vgontzas, 2000 [30] USA Mixed 14/23 46.6 ± 3.0 38.4 ± 1.6 48.7 ± 5.6 43.6 ± 2.5 30.7 ± 1.56 0.88 ± 0.4 Plasma 
Ciftci, 2004 [31] Turkey Caucasian 43/22 49.6 ± 9.1 31.9 ± 4.1 33.2 ± 5.0 47.2 ± 10.3 31.03 ± 3.1 1.55 ± 0.96 Serum 
Imagawa, 2004 [32] Japan Asian 118/47 Adult 27.7 ± 4.4 ≥5 Adult 22.9 ± 2.9 <5 Serum 
Minoguchi, 2004 [16] Japan Asian 24/27 50.1 ± 11.7 29.1 ± 2.2 34.1 ± 14.7 48.11 ± 10.5 25.3 ± 1.25 2.27 ± 1.95 Serum 
Tazaki, 2004 [33] Japan Asian 48/18 50.6 ± 4.8 28.9 ± 1.6 36.05 ± 1.75 48.2 ± 3.0 27.8 ± 0.8 3.7 ± 0.4 Serum 
Ryan, 2005 [34] Ireland Caucasian 19/17 39.5 ± 20 32.32 ± 16.07 49.6 ± 25.25 39.5 ± 19.5 31.05 ± 15.55 1.03 ± 0.52 Serum 
Kobayashi, 2006 [35] Japan Asian 35/16 51.4 ± 13.1 27.9 ± 3.6 52.26 ± 14.76 41 ± 13.1 27.4 ± 3.7 <5 Serum 
Ryan, 2006 [36] Ireland Caucasian 66/30 42.5 ± 8.5 32.5 ± 4.8 35.0 ± 13.9 41 ± 8 30.7 ± 3.1 1.2 ± 1.0 Serum 
de la Peña Bravo, 2007 [38] USA Mixed 50/20 51.7 ± 1.9 33.2 ± 1.7 51.3 ± 4.2 47.4 ± 1.2 28.4 ± 0.6 2.5 ± 0.5 Serum 
Arias, 2008 [39] Spain Caucasian 30/15 52.0 ± 13.0 30.5 ± 4.0 43.8 ± 27.0 48.0 ± 10.0 28.7 ± 4.7 3.7 ± 3.3 Plasma 
Constantinidis, 2008 [40] Greece Caucasian 24/27 45.1 ± 8.2 ≥25 23.3 ± 3.6 45.1 ± 8.2 ≥25 3.5 ± 0.4 Serum 
Kanbay, 2008 [41] Turkey Caucasian 106/32 51.39 ± 10.37 31.06 ± 5.87 40.14 ± 14.30 44.79 ± 13.35 28.25 ± 5.49 1.96 ± 1.08 Serum 
Tomiyama, 2008 [43] Japan Asian 50/15 51.4 ± 13.0 26.9 ± 4.2 42.7 ± 27.9 53.0 ± 10.0 24.3 ± 2.5 <5 Plasma 
Carneiro, 2009 [44] Brazil Mixed 16/13 40.1 ± 2.8 46.9 ± 2.0 65.7 ± 9.9 38.8 ± 3.3 42.8 ± 1.3 3.2 ± 0.5 Plasma 
Li, 2009 [45] China Asian 68/22 45.3 ± 11.1 20.7 ± 10.1 38.9 ± 26.5 43.0 ± 93.0 23.3 ± 2.0 2.9 ± 1.3 Serum 
Thomopoulos, 2009 [46] Greece Caucasian 62/70 48.1 ± 7.6 31.9 ± 4.9 31.6 ± 2.0 48.1 ± 3.9 32.1 ± 3.0 0.4 ± 4.0 Serum 
Sahlman, 2010 [47] Finland Caucasian 84/40 50.4 ± 9.3 32.5 ± 3.3 9.6 ± 2.9 45.6 ± 11.5 31.5 ± 3.5 1.9 ± 1.4 Plasma 
Steiropoulos, 2010 [48] Greece Caucasian 38/23 45.5 ± 10.5 36.4 ± 7.4 61.0 ± 27.0 43.7 ± 6.7 34.5 ± 3.7 5.3 ± 3.2 Serum 
Sarac, 2011 [49] Turkey Caucasian 62/26 50.0 ± 19.7 33.7 ± 4.2 29.5 ± 1.9 49.7 ± 11.1 34.3 ± 5.4 <5 Plasma 
Fornadi, 2012 [50] Canada Mixed 25/75 54.0 ± 12.0 29.0 ± 5.0 ≥5 50.0 ± 13.0 26.0 ± 5.0 <5 Serum 
Medeiros, 2012 [51] Brazil Mixed 50/15 62.3 ± 7.8 25.5 ± 4.0 ≥5 62.50 ± 8.4 25.8 ± 4.0 <5 Serum 
Qian, 2012 [52] China Asian 70/40 45.8 ± 8.2 28.9 ± 2.3 ≥5 46.3 ± 8.1 24.1 ± 2.3 <5 Serum 
Chen, 2013 [54] China Asian 44/20 21.4 ± 11.95 27.12 ± 3.53 14.56 ± 2.85 42 ± 11 26.0 ± 3.3 3.3 ± 0.9 Plasma 
Hargens, 2013 [56] USA Mixed 12/33 22.8 ± 0.8 32.4 ± 1.0 25.4 ± 5.4 21.9 ± 0.6 29.3 ± 0.5 2.1 ± 0.3 Serum 
Matos, 2013 [57] Brazil Mixed 119/187 51.2 29.7 ≥5 40.7 24.5 <5 Plasma 
Yang, 2013 [58] China Asian 50/25 53.5 ± 6.9 27.4 ± 2.9 24.5 ± 15.9 53.0 ± 7.0 26.27 ± 1.9 3.0 ± 1.0 Plasma 
Ciccone, 2014 [59] Italy Caucasian 80/40 52.8 ± 10.6 28.6 ± 3.0 33.9 ± 21 52.3 ± 10.5 28.2 ± 2.7 2.1 ± 1.1 Plasma 
Sun, 2014 [60] China Asian 121/18 43.3 ± 11.6 27.1 ± 3.1 40.8 ± 10.9 43.9 ± 13.4 25.7 ± 3.8 2.1 ± 1.8 Serum 
Unuvar Dogan, 2014 [61] Turkey Caucasian 33/24 45.3 ± 8.5 31.0 ± 1.7 47.2 ± 23.2 40.5 ± 9.5 30.7 ± 1.5 3.6 ± 1.8 Serum 
Chen, 2015 [62] China Asian 93/28 42.28 ± 8.55 28.84 ± 3.82 27 ± 4.06 43.7 ± 9.8 26.4 ± 2.5 2.6 ± 1.2 Plasma 
De, 2015 [63] Italy Caucasian 26/24 41.8 ± 7.4 33.0 ± 5.2 26.15 ± 12.1 43.7 ± 8.2 30.8 ± 4.3 1.65 ± 0.9 Serum 
Jiang, 2015 [64] China Asian 135/94 48.7 ± 12.1 27.48 ± 2.56 24.57 ± 15.9 47.2 ± 13.5 27.52 ± 2.58 1.60 ± 1.61 Serum 
Thunström, 2015 [65] Sweden Caucasian 234/95 65.3 ± 7.1 26.8 ± 2.1 28.9 ± 13.7 61.4 ± 9.5 25.2 ± 2.5 3.1 ± 1.3 Serum 
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Lin, 2016 [67] Taiwan Asian 35/20 46 ± 7 29.2 ± 1.9 59.3 ± 23.2 43 ± 8 28.2 ± 1.6 3.6 ± 0.8 Serum 
Nizam, 2016 [68] Turkey Caucasian 39/13 47.3 ± 10.4 33.2 ± 56.4 45.6 ± 20.7 43.23 ± 9.08 31.71 ± 4.56 2.64 ± 1.82 Serum 
Vicente, 2016 [69] Spain Caucasian 89/26 45.33 ± 14.81 30.03 ± 5.04 28 ± 23.70 45 ± 11.11 28.7 ± 4.37 1.9 ± 2.7 Plasma 
Hirotsu, 2017 [70] Brazil Mixed 339/682 50.8 ± 13.2 29.6 ± 5.8 19.3 ± 9.44 38.2 ± 12.7 25.4 ± 3.8 2.5 ± 10.4 Serum 
Jiang, 2017 [71] China Asian 120/40 24.82 ± 10.7 28.5 ± 5.13 46.6 ± 4.56 46.5 ± 12.3 27.5 ± 6.2 2.13 ± 1.26 Plasma 
Jin, 2017 [72] China Asian 100/50 55.28 ± 7.13 26.75 ± 3.50 38.01 ± 8.04 56.13 ± 6.21 25.19 ± 2.45 3.62 ± 1.54 Plasma 
Bozic, 2018 [75] Croatia Caucasian 50/25 53.0 ± 11.9 28.9 ± 2.7 35.0 ± 11.0 52.5 ± 10.2 27.8 ± 2.2 <5 Plasma 
Kong, 2018 [76] China Asian 50/40 54.34 ± 14.38 26.86 ± 3.12 37.34 ± 19.02 50.42 ± 8.35 22.26 ± 3.54 3.31 ± 1.09 Serum 
Ming, 2019 [78] China Asian 684/192 51.34 ± 5.16 ≤30 31.15 ± 9.12 52.18 ± 4.51 ≤30 4.34 ± 2.01 Serum 
Tang, 2019 [79] China Asian 120/127 48.88 ± 9.76 26.86 ± 3.12 39.00 ± 18.38 47.37 ± 9.12 22.46 ± 3.29 3.31 ± 1.09 Serum 
Galati, 2020 [80] Italy Caucasian 45/30 53.9 ± 11.6 28 ± 2.2 ≥5 55 ± 5.8 26.3 ± 1.8 <5 Serum 
PEDIATRICS 
Tam, 2006 [37] Australia Mixed 44/69 7.3 ± 3.7 19.4 ± 5.5 5.3 ± 6.5 7.6 ± 4.0 17.9 ± 3.9 0 ± 0 Serum 
Li, 2008 [42] China Asian 47/95 11.1 ± 1.27 NR 14.1 ± 8.0 10.7 ± 1.3 NR 0.7 ± 0.6 Serum 
Alexopoulos, 2013 [53] Greece Caucasian 24/44 5.7 ± 2 <25 11.5 ± 5.1 6.4 ± 2.3 <25 1.3 ± 0.65 Plasma 
Chu, 2013 [55] China Asian 55/35 Child NR ≥5 Child NR <5 Plasma 
Gaines, 2016 [66] USA Mixed 44/348 18.41 ± 2.2 NR 12.08 ± 4.64 18.4 ± 2.2 NR 1.65 ± 4.81 Plasma 
Huang, 2016 [14] Taiwan Asian 47/32 7.84 ± 0.56 16.95 ± 0.47 9.13 ± 1.67 7.02 ± 0.65 6.55 ± 0.58 0.41 ± 0.07 Plasma 
Smith, 2017 [73] USA Mixed 33/98 9.0 ± 2.7 23.4 ± 13.5 15.2 ± 11.7 19.66 ± 4.44 9.68 ± 2.5 1.03 ± 0.46 Plasma 
Zhang, 2017 [74] China Asian 50/52 6.6 NR ≥5 6.4 NR <5 Serum 
Rogers, 2018 [77] USA Mixed 20/7 7.9 ± 2.2 <25 13.1 ± 9.8 7.9 ± 2.2 <25 0.8 ± 0.3 Serum 
NR, Not reported; OSAS, Obstructive sleep apnea syndrome; AHI, Apnea-hypopnea index; BMI, Body mass index. 
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3.3. Overall Analysis 
3.3.1. Serum Levels of TNF-α in Adults 
Twenty-nine studies compared serum TNF-α concentrations between adults with OSAS and 
healthy controls (Figure 2); adults with OSAS had significantly higher TNF-α concentrations 
compared to healthy controls: 10.22 pg/mL (95% CI = 8.86, 11.58; p < 0.00001; I2 = 100% (Ph or 
Pheterogeneity < 0.00001)). 
 
Figure 2. Forest plot of serum tumor necrosis factor alpha levels in adult participants with 
obstructive sleep apnea syndrome patients compared to controls. 
3.3.2. Plasma Levels of TNF-α in Adults 
Seventeen studies compared plasma TNF-α concentrations between adults with OSAS and 
healthy controls (Figure 3) and found significantly higher TNF-α concentrations in those with 
OSAS: 5.90 pg/mL (95% CI = 4.00, 7.80; p < 0.00001; I2 = 99% (Ph < 0.00001)). 
 
Life 2020, 10, 87 9 of 27 
  
Figure 3. Forest plot of plasma tumor necrosis factor alpha levels in adult participants with 
obstructive sleep apnea syndrome patients compared to controls. 
3.3.3. Serum TNF-α Levels in Children 
Four studies compared serum TNF-α concentrations between children with OSAS and without 
OSAS (Figure 4) and found significantly higher TNF-α concentrations in those with OSAS: 0.21 
pg/mL (95% CI = 0.05, 0.37; p = 0.01; I2 = 77% [Ph = 0.005]. 
 
Figure 4. Forest plot of serum tumor necrosis factor alpha levels in pediatric participants with 
obstructive sleep apnea syndrome patients compared to controls. 
3.3.4. Plasma TNF-α Levels in Children 
Five studies compared serum TNF-α concentrations between children with OSAS and without 
OSAS (Figure 5) and found no statistically significant MDs: 0.15 pg/mL (95% CI = −0.16, 0.45; p = 
0.35; I2 = 61% [Ph = 0.04]). 
 
Figure 5. Forest plot of plasma tumor necrosis factor alpha levels in pediatric participants with 
obstructive sleep apnea syndrome patients compared to controls. 
3.4. Overall Subgroup Analysis of Serum and Plasma TNF-α Levels 
3.4.1. Ethnicity 
Subgroup analysis of serum TNF-α concentrations in adult samples are reported in Table 2. The 
pooled analysis showed that for those with OSAS, serum TNF-α concentrations in Asians (MD = 37.11 
pg/mL (95% CI = 33.27, 40.95; p < 0.00001), in Caucasians (MD = 2.20 pg/mL; 95% CI = 1.06, 3.34; p = 
0.0002), and in mixed ethnicities (MD = 0.43; 95% CI = 0.30, 0.56; p < 0.00001) were significantly higher, 
compared to healthy controls. Serum TNF-α concentrations in Asians were 16.9 and 86.3 times higher 
than serum TNF-α concentrations in Caucasian and mixed ethnicities with OSAS, and always compared 
to controls. 
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Table 2. Subgroup analysis on serum and plasma levels of tumor necrosis factor alpha in adult 
participants. 
Subgroup Analysis 
of Serum Level (n) 
MD (95%CI), p-Value, I2 (%), 
Ph 
Subgroup Analysis 
of Plasma Level (n) 
MD (95%CI), p-Value, I2 
(%), Ph 
Overall (29) 
10.22 (8.86, 11.58), <0.00001; 100, 
<0.00001 
Overall (17) 
5.41 (3.66, 7.15), <0.00001, 
99, <0.00001 
Ethnicity - Ethnicity  
Caucasian (12) 
2.20 (1.06, 3.34),0.0002, 94, 
<0.00001 
Caucasian (6) 
3.72 (1.04, 6.40), 0.007, 99, 
<0.00001 
Asian (12) 
37.11 (33.27, 40.95), <0.00001, 
100, <0.00001 
Asian (7) 
14.92 (9.86, 19.98), 
<0.00001, 100, <0.00001 
Mixed (5) 
0.43 (0.30, 0.56), <0.00001, 26, 
0.25 
Mixed (4) 
1.22 (0.10, 2.34), 0.03, 93, 
<0.00001 
Mean BMI of OSAS 
patients, kg/m2 
- 
Mean BMI of OSAS 
patients, kg/m2 
- 
>30 (11) 
1.27 (0.67, 1.86), <0.0001, 95, 
<0.000001 
>30 (7) 
1.06 (0.34, 1.78), 0.004, 91, 
<0.00001 
≤30 (17) 
23.07 (20.18, 25.96), <0.00001, 
100, <0.00001 
≤30 (10) 
10.82 (7.14, 14.49), 
<0.00001, 99, <0.00001 
Mean BMI of 
controls, kg/m2 
- 
Mean BMI of 
controls, kg/m2 
- 
>30 (8) 
2.28 (0.86, 3.70), 0.002, 95, 
<0.00001 
>30 (4) 
1.19 (0.00, 2.38), 0.05, 92, 
<0.00001 
≤30 (20) 
18.64 (16.33, 20.95), <0.00001, 
100, <0.00001 
≤30 (13) 
7.32 (5.02, 9.62), <0.00001, 
99, <0.00001 
Total number of 
participants  
- 
Total number of 
participants 
- 
>100 (10) 
55.47 (47.21, 63.72), <0.00001, 
100, <0.00001 
>100 (7) 
6.91 (2.20, 11.63), 0.004, 
100, <0.00001 
≤100 (19) 
2.15 (1.57, 2.72), <0.00001, 98, 
<0.00001 
≤100 (10) 
2.87 (1.37, 4.37), 0.0002, 
98, <0.00001 
Mean AHI of OSAS 
patients, events/h 
- 
Mean AHI of OSAS 
patients, events/h 
- 
>30 (18) 
5.72 (4.32, 7.12), <0.00001, 100, 
<0.00001 
>30 (10) 
8.15 (5.59, 10.71), 
<0.00001, 99, <0.00001 
≤30 (6) 
127.01 (100.56, 153.47), <0.00001, 
100, <0.00001 
≤30 (6) 
2.97 (0.21, 5.73), 0.03, 99, 
<0.00001 
BMI, Body mass index; CI, Confidence interval; OSAS, Obstructive sleep apnea syndrome; MD, 
Mean difference; Ph, Pheterogeneity. Bold numbers show statistically significant value (p-value < 0.05). 
For plasma TNF-α concentrations, for those adults with OSAS, plasma TNF-α concentrations 
in Asians (MD = 14.92 pg/mL; 95% CI = 9.86, 19.98; p < 0.00001), in Caucasians (MD = 3.72 (95% CI = 
1.04, 6.40; p = 0.007)), and in mixed ethnicities (MD = 1.22; 95% CI = 0.10, 2.34; p = 0.03) were 
significantly higher, compared to healthy controls. Next, in Asians, plasma TNF-α concentrations 
were 4 and 12.2 times higher than in Caucasian and mixed ethnicities with OSAS, and always 
compared to controls. 
3.4.2. Mean BMI of Individuals with OSAS 
For serum TNF-α concentrations, and compared to healthy controls, adult participants with 
OSAS and a BMI > 30 km/m2 showed a pooled MD of 1.27 (95% CI: 0.67, 1.86; p < 0.0001). For adult 
participants with OSAS and a BMI ≤ 30 km/m2, the pooled MD was 23.07 pg/mL (95% CI: 20.18, 
25.96; p < 0.00001). Thus, results showed that serum TNF-α concentrations were 18.2 times higher 
participants with OSAS and a BMI > 30 kg/m2, when compared to those participants with a mean 
BMI ≤30 kg/m2. 
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For plasma TNF-α concentrations, and compared to healthy controls, adult participants with 
OSAS and a BMI > 30 km/m2 showed a pooled MD of 1.06 pg/mL (95% CI: 0.34, 1.78; p = 0.004). For 
adult participants with OSAS and a BMI ≤ 30 km/m2, the pooled MD was 10.82 pg/mL (95% CI: 7.14, 
14.49; p < 0.00001). Thus, results showed that plasma TNF-α concentrations were 10.2 times higher 
in adults with OSAS and a BMI > 30 kg/m2 than plasma TNF-α concentrations of adults with OSAS 
and a BMI ≤ 30 kg/m2 and always compared to healthy controls. 
3.4.3. Mean BMI of Controls 
For serum TNF-α levels, compared to controls, individuals with OSAS and with a BMI > 30 
kg/m2 showed a pooled MD of 2.28 pg/mL (95% CI: 0.86, 3.70; p = 0.002); while compared to 
controls, individuals with OSAS and with a BMI ≤ 30 kg/m2 showed a pooled MD of 18.64 pg/mL 
(95% CI: 16.33, 20.95; p < 0.00001). Thus, serum TNF-α levels were 8.2 times higher in studies with 
participants with OSAS and a BMI >30 kg/m2 than serum TNF-α levels with participants with OSAS 
and a BMI ≤ 30 kg/m2. 
For plasma TNF-α levels, compared to controls, the pooled MD was 7.32 pg/mL (95% CI: 5.02, 
9.62; p < 0.00001) for participants with OSAS and a BMI > 30 kg/m2; for participants with OSAS and 
a BMI ≤ 30 kg/m2, the pooled MD was not statistically significant (MD = 1.19 pg/mL; 95% CI: 0.00, 
2.38; p = 0.05). 
3.4.4. Total Number of Participants 
For serum TNF-α levels, the pooled MD was 55.47 pg/mL (95% CI: 47.21, 63.72; p < 0.00001) for 
studies with more than 100 cases, and 2.15 pg/mL (95% CI: 1.57, 2.72; p < 0.00001) for studies with 
less than 100 cases. Thus, serum TNF-α levels were 25.8 times higher in the studies with more 100 
cases, compared to studies with less than 100 cases. 
For plasma TNF-α levels, the pooled MD was 6.91 pg/mL (95%CI: 2.20, 11.63; p = 0.004) for 
studies with more than 100 cases, while the pooled MD was 2.87 pg/mL (95%CI: 1.37, 4.37; p = 
0.0002) for studies with less than 100 cases. Thus, plasma TNF-α levels were 2.4 times higher in the 
studies with more than 100 cases, compared to studies with less than 100 cases. 
3.4.5. Mean AHI of Individuals with OSAS 
For serum TNF-α levels, in individuals with OSAS and a AHI > 30 events/h, the pooled MD 
was 5.72 pg/mL (95% CI: 4.32, 7.12; p < 0.00001), while the pooled MD was 127.01 pg/mL (95%CI: 
100.56, 153.47; p < 0.00001) in individuals with OSAS and a AHI ≤ 30 events/h. Thus, serum TNF-α 
levels were 22.2 times higher, when participants with OSAS had AHI ≤ 30 events/h, compared to 
AHI > 30 events/h. 
For plasma TNF-α levels, in individuals with OSAS and AHI > 30 events/h, the pooled MD 
was 8.15 pg/mL (95% CI: 5.59, 10.71; p < 0.00001), while in individuals with OSAS and AHI ≤ 30 
events/h, the pooled MD was 2.97 pg/mL (95% CI: 0.21, 5.73; p = 0.03). Thus, serum TNF-α levels 
were 2.7 times higher in participants with OSAS and AHI > 30 events/h, compared to serum TNF-α 
levels in participants with OSAS and AHI ≤ 30 events/h. 
3.5. Adult Caucasian Participants 
3.5.1. Mean BMI of Individuals with OSAS 
For serum TNF-α levels, studies with Caucasian participants with OSAS and a BMI > 30 kg/m2 
showed the pooled MD of 2.58 pg/mL (95% CI: 1.07, 4.10; p = 0.0008), whereas for studies with 
participants with a BMI ≤ 30 kg/m2 serum TNF-α levels did not statistically differ between 
participants with or without OSAS (Table 3). 
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Table 3. Subgroup analysis on serum and plasma levels of tumor necrosis factor alpha in adult 
Caucasian participants. 
Subgroup Analysis of 
Serum Level (n) 
MD (95%CI), p-Value, 
I2 (%), Ph 
Subgroup Analysis of 
Plasma Level (n) 
MD (95%CI), p-Value, 
I2 (%), Ph 
Overall (12) 
2.20 (1.06, 3.34), 0.0002, 
94, <0.00001 
Overall (6) 
3.72 (1.04, 6.40), 0.007, 
99, <0.00001 
Mean BMI of OSAS 
patients, kg/m2 
 
Mean BMI of OSAS 
patients, kg/m2 
 
>30 (9) 
2.58 (1.07, 4.10), 0.0008, 
95, <0.00001 
>30 (4) 
0.43 (−0.010, 0.96), 0.11, 
50, 0.11 
≤30 (2) 
1.70 (−0.32, 3.71), 0.10, 
82, 0.02 
≤30 (2) 
7.99 (1.84, 14.15), 0.01, 
98, <0.00001 
Mean BMI of controls, 
kg/m2 
 
Mean BMI of controls, 
kg/m2 
 
>30 (8) 
2.28 (0.86, 3.70), 0.002, 
95, <0.00001 
>30 (2) 
0.56 (0.05, 1.08), 0.03, 
18, 27 
≤30 (3) 
3.29 (−1.09, 7.67), 0.14, 
93, <0.00001 
≤30 (4) 
5.64 (0.77, 10.52), 0.02, 
99, <0.00001 
Total number of 
participants  
 
Total number of 
participants 
 
>100 (3) 
1.13 (−0.78, 3.04), 0.25, 
91, <0.0001 
>100 (3) 
3.82 (−0.22, 7.85), 0.06, 
99, <0.00001 
≤100 (9) 
3.21 (1.37, 5.05), 0.0006, 
95, <0.00001 
≤100 (3) 
3.52 (0.03, 7.02), 0.05, 
95, <0.00001 
Mean AHI of OSAS 
patients, events/h 
 
Mean AHI of OSAS 
patients, events/h 
 
>30 (8) 
1.40 (0.34, 2.46), 0.010, 
91, <0.00001 
>30 (3) 
7.80 (2.47, 13.13), 0.004, 
97, <0.00001 
≤30 (2) 
23.20 (−28.02, 74.41), 
0.37, 85, 0.01 
≤30 (3) 
0.26 (−0.01, 0.53), 0.06, 
34, 0.22 
BMI, Body mass index; CI, Confidence interval; OSAS, Obstructive sleep apnea syndrome; MD, 
Mean difference; Ph, Pheterogeneity. Bold numbers show statistically significant value (p-value < 0.05). 
For plasma TNF-α levels, studies with Caucasian participants with OSAS and a BMI ≤ 30 kg/m2 
showed the pooled MD of 7.99 pg/mL (95% CI: 1.84, 14.15; p = 0.01), whereas no significant MDs 
were observed in studies including Caucasian participants with OSAS and a BMI > 30 kg/m2. 
3.5.2. Mean BMI of Controls 
For studies with serum TNF-α levels and Caucasian controls with a mean BMI > 30 kg/m2, the 
pooled MD was 2.58 pg/mL (95% CI: 1.07, 4.10; p = 0.0008). There was no statistically significant MD 
for serum TNF-α levels between Caucasians with or without OSAS and a mean ≤ 30 kg/m2. 
For studies with plasma TNF-α levels and controls with a BMI > 30 kg/m2, the pooled MD was 
0.56 pg/mL (95% CI: 0.05, 1.08; p = 0.03). Studies with controls with a BMI ≤ 30 kg/m2 showed a 
pooled MD of 5.64 pg/mL (95% CI: 0.77, 10.52; 0.02). Thus, plasma TNF-α levels were 10.1 times 
higher in controls with a BMI ≤ 30 kg/m2, compared to plasma TNF-α levels of controls with a BMI 
> 30 kg/m2 
3.5.3. Total Number of Participants 
Serum TNF-α levels had a significant difference in studies with ≤ 100 cases (MD = 3.21 pg/mL; 
95% CI: 1.37, 5.05; p = 0.0006), whereas there was no significant difference for studies with >100 
cases. 
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3.5.4. Mean AHI of Individuals with OSAS 
In studies with individuals with OSAS and AHI of > 30 events/h, serum TNF-α levels were 1.40 
pg/mL (95% CI: 0.34, 2.46; p = 0.010), and plasma TNF-α levels were 7.80 pg/mL (95% CI: 2.47, 13.13; 
p = 0.004). 
3.6. Adult Asian Participants 
3.6.1. Mean BMI of Individuals with OSAS 
For serum and plasma TNF-α levels, there were no Asian participants with OSAS and a mean 
BMI > 30 kg/m2. For studies with Asian participants with OSAS and a mean BMI ≤ 30 kg/m2, serum 
(MD = 37.11 pg/mL; 95% CI: 33.27, 25.96; p < 0.0001) and plasma (MD = 14.92 pg/mL; 95% CI: 9.86, 
19.98; p < 0.00001) TNF-α levels differed statistically significantly (Table 4). 
Table 4. Subgroup analysis on serum and plasma levels of tumor necrosis factor alpha in adult 
Asian participants. 
Subgroup Analysis of 
Serum Level (n) 
MD (95%CI), p-Value, I2 
(%), Ph 
Subgroup Analysis of 
Plasma Level (n) 
MD (95%CI), p-Value, 
I2 (%), Ph 
Overall (12) 
37.11 (33.27, 40.95), 
<0.00001, 100, <0.00001 
Overall (7) 
14.92 (9.86, 19.98), 
<0.00001, 100, <0.00001 
Mean BMI of OSAS 
patients, kg/m2 
- 
Mean BMI of OSAS 
patients, kg/m2 
- 
>30 (0) - >30 (0) - 
≤30 (12) 
37.11 (33.27, 40.95), 
<0.00001, 100, <0.00001 
≤30 (7) 
14.92 (9.86, 19.98), 
<0.00001, 100, <0.00001 
Mean BMI of controls, 
kg/m2 
- 
Mean BMI of controls, 
kg/m2 
- 
>30 (0) - >30 (0) - 
≤30 (12) 
37.11 (33.27, 40.95), 
<0.00001, 100, <0.00001 
≤30 (7) 
14.92 (9.86, 19.98), 
<0.00001, 100, <0.00001 
Total number of 
participants  
- 
Total number of 
participants 
- 
>100 (6) 
89.88 (74.59, 105.17), 
<0.00001, 100, <0.00001 
>100 (3) 
12.34 (7.84, 16.84), 
<0.00001, 97, <0.00001 
≤100 (6) 
7.80 (5.76, 9.85), <0.00001, 
99, <0.00001 
≤100 (4) 
21.51 (13.15, 29.87), 
<0.00001, 99, <0.00001 
Mean AHI of OSAS 
patients, events/h 
- 
Mean AHI of OSAS 
patients, events/h 
- 
>30 (9) 
12.94 (7.74, 18.13), 
<0.00001, 100, <0.00001 
>30 (4) 
12.48 (17.04, 31.52), 
<0.00001, 100, <0.00001 
≤30 (0) - ≤30 (3) 
5.45 (−3.55, 14.45), 0.24, 
99, <0.00001 
BMI, Body mass index; CI, Confidence interval; OSAS, Obstructive sleep apnea syndrome; MD, 
Mean difference; Ph, Pheterogeneity. Bold numbers show statistically significant value (p-value < 0.05). 
3.6.2. Mean BMI of Controls 
For serum and plasma TNF-α levels, there were no studies including controls with a BMI > 30 
kg/m2. The serum TNF-α levels were 37.11 pg/mL (95% CI: 33.27, 25.96; p < 0.0001) for studies 
including OSAS patients with a mean BMI of ≤ 30 kg/m2, and plasma TNF-α levels were 14.92 
pg/mL (CI: 9.86, 19.98; p < 0.00001) for studies including OSAS patients with a mean BMI of ≤ 30 
kg/m2. 
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3.6.3. Total Number of Participants 
For serum TNF-α levels, the pooled MD was 89.88 pg/mL (95% CI: 74.59, 105.17; p < 0.00001) 
for studies with 100 or more participants, and the pooled MD was 7.80 pg/mL (95% CI: 5.76, 9.85; p 
< 0.00001) for studies less than 100 participants. Thus, serum TNF-α levels were 11.5 times higher in 
studies with more than 100 participants, compared to studies with less than 100 participants. 
For plasma TNF-α levels, the pooled MD was 12.34 pg/mL (95%CI: 7.84, 16.84; p < 0.00001) for 
studies with 100 or more participants, and the pooled MD was 21.51 pg/mL (95%CI: 13.15, 29.87; p < 
0.00001) for studies less than 100 participants. Thus, plasma TNF-α levels were 1.7 times higher in 
studies with less than 100 participants, compared to studies with more than 100 participants. 
3.6.4. Mean AHI of Individuals with OSAS 
No study investigated serum and plasma TNF-α levels in participants with OSAS with a mean 
AHI ≤ 30 events/h. 
For studies including AHI > 30 events/h, mean serum TNF-α levels were 12.94 (pg/mL; 95% CI: 
7.74, 18.13; p < 0.00001); plasma TNF-α levels were 12.48 pg/mL (95% CI: 17.04, 31.52; p < 0.00001). 
3.7. Adult Participants Including Mean BMI of Individuals with OSAS > 30 kg/m2 
3.7.1. Mean BMI of Controls 
For studies with serum TNF-α levels and controls with BMI of controls >30 kg/m2, there was a 
significant difference for serum TNF-α levels (MD = 2.28 pg/mL; 95% CI: 0.86, 3.70; p = 0.002), 
compared to studies with controls with BMI of controls ≤ 30 kg/m2 (Table 5). 
Table 5. Subgroup analysis on serum and plasma levels of tumor necrosis factor alpha in adult 
participants including mean BMI of OSAS patients >30 kg/m2. 
Subgroup Analysis of 
Serum Level (n) 
MD (95%CI), p-Value, I2 
(%), Ph 
Subgroup Analysis of 
Plasma Level (n) 
MD (95%CI), p-
Value, I2 (%), Ph 
Overall (11) 
1.27 (0.67, 1.86), <0.0001, 
95, <0.000001 
Overall (7) 
1.06 (0.34, 1.78), 0.004, 
91, <0.00001 
Mean BMI of controls, 
kg/m2 
- 
Mean BMI of controls, 
kg/m2 
- 
>30 (8) 
2.28 (0.86, 3.70), 0.002, 
95, <0.00001 
>30 (4) 
1.19 (0.00, 2.38), 0.05, 
92, <0.00001 
≤30 (3) 
40.64 (−24.23, 105.51), 
0.22, 92, <0.00001 
≤30 (3) 
0.88 (−0.30, 2.07), 0.14, 
93, <0.00001 
Total number of 
participants  
- 
Total number of 
participants 
- 
>100 (2) 
34.66 (−34.62, 103.93), 
0.33, 95, <0.00001 
>100 (2) 
0.20 (−0.09, 0.48), 0.17, 
0, 0.53 
≤100 (9) 
1.27 (0.65, 1.89), <0.0001, 
95, <0.00001 
≤100 (5) 
1.51 (0.53, 2.49), 0.003, 
90, <0.00001 
Mean AHI of OSAS 
patients, events/h 
- 
Mean AHI of OSAS 
patients, events/h 
- 
>30 (9) 
0.96 (0.50, 1.42), <0.0001, 
92, <0.00001 
>30 (4) 
1.69 (0.47, 2.90), 0.007, 
92, <0.00001 
≤30 (2) 
42.13 (33.48, 50.77), 
<0.00001, 0, 0.58 
≤30 (3) 
0.26 (−0.01, 0.53), 0.06, 
34, 0.22 
BMI, Body mass index; CI, Confidence interval; OR, OSAS, Obstructive sleep apnea syndrome; MD, 
Mean difference; Ph, Pheterogeneity. Bold numbers show statistically significant value (p-value < 0.05). 
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3.7.2. Total Number of Participants 
For studies with 100 or less participants, there was a significant difference for serum TNF-α 
levels (MD = 1.27 pg/mL; 95% CI: 0.65, 1.89; p < 0.0001) and for plasma TNF-α levels (MD = 1.51 
pg/mL; 95% CI: 0.53, 2.49; p = 0.003), compared to studies with more than 100 participants. 
3.7.3. Mean AHI of Participants with OSAS 
For serum TNF-α levels, the pooled MD for studies including participants with OSAS with 
AHI > 30 events/h was 0.96 pg/mL (95% CI: 0.50, 1.42; p < 0.0001); the pooled MD for studies with 
participants with OSAS with AHI ≤ 30 events/h was 42.13 pg/mL (95%CI: 33.48, 50.77; p < 0.00001). 
Thus, serum TNF-α levels were 42.9 times higher in studies with participants with OSAS and AHI ≤ 
30 events/h, compared to the serum TNF-α levels in studies including participants with OSAS and 
AHI > 30 events/h. 
For plasma TNF-α levels, the pooled MD for studies with participants with OSAS with AHI > 
30 events/h was 1.69 pg/mL (95% CI: 0.47, 2.90; p = 0.007). When studies included participants with 
OSAS and an AHI ≤ 30 events/h, MDs between studies with participants with or without OSAS 
were not significant. 
3.8. Adult Participants with a Mean BMI ≤ 30 kg/m2 in Participants with OSAS 
3.8.1. Mean BMI of Controls 
No study investigated serum and plasma TNF-α levels in participants with OSAS with a mean 
BMI >30 kg/m2. 
For studies including BMI ≤ 30 kg/m2 in controls, TNF-α levels were 23.07 pg/mL (95% CI: 
20.18, 4.50; p < 0.00001) for serum, and MD = 10.82 pg/mL (95% CI: 7.14, 14.49; p < 0.00001) for 
plasma (Table 6). 
Table 6. Subgroup analysis on serum and plasma levels of tumor necrosis factor alpha in adult 
participants including mean BMI of OSAS patients ≤ 30 kg/m2. 
Subgroup Analysis of 
Serum Level (n) 
MD (95%CI), p-Value, I2 
(%), Ph 
Subgroup Analysis of 
Plasma Level (n) 
MD (95%CI), p-Value, 
I2 (%), Ph 
Overall (17) 
23.07 (20.18, 4.50), 
<0.00001, 100, <0.00001 
Overall (10) 
10.82 (7.14, 14.49), 
<0.00001, 99, <0.00001 
Mean BMI of controls, 
kg/m2 
 
Mean BMI of controls, 
kg/m2 
 
>30 (0) - >30 (0) - 
≤30 (17) 
23.07 (20.18, 4.50), 
<0.00001, 100, <0.00001 
≤30 (10) 
10.82 (7.14, 14.49), 
<0.00001, 99, <0.00001 
Total number of 
participants  
 
Total number of 
participants 
 
>100 (8) 
63.51 (53.65, 73.45), 
<0.00001, 100, <0.00001 
>100 (6) 
8.12 (4.46, 11.79), 
<0.0001, 98, <0.00001 
≤100 (9) 
4.42 (3.10, 5.74), <0.00001, 
98, <0.00001 
≤100 (4) 
13.79 (8.24, 19.35), 
<0.00001, 99, <0.00001 
Mean AHI of OSAS 
patients, events/h 
 
Mean AHI of OSAS 
patients, events/h 
 
>30 (9) 
12.94 (7.74, 18.13), 
<0.00001, 100, <0.00001 
>30 (6) 
16.13 (11.20, 21.06), 
<0.00001, 100, <0.00001 
≤30 (3) 
173.00 (139.66, 206.34), 
<0.00001, 100, <0.00001 
≤30 (3) 
5.45 (−3.55, 14.45), 0.24, 
99, <0.00001 
BMI, Body mass index; CI, Confidence interval; OR, OSAS, Obstructive sleep apnea syndrome; MD, 
Mean difference; NA, Not available; Ph, Pheterogeneity. Bold numbers show statistically significant 
value (p-value < 0.05). 
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3.8.2. Total Number of Participants 
For serum TNF-α levels and in studies with more than 100 participants, the pooled MD was 
63.51 pg/mL (95% CI: 53.65, 73.45; p < 0.00001), while in studies with ≤ 100 participants, the pooled 
MD was 4.42 pg/mL (95% CI: 3.10, 5.74; p < 0.00001). Thus, serum TNF-α levels were 14.4 times 
higher in studies with more than 100 participants, compared to serum TNF-α levels in studies with 
≤100 participants. 
For plasma TNF-α levels and in studies with more than 100 participants, the pooled MD was 
8.12 pg/mL (95%CI: 4.46, 11.79; p < 0.0001) while in studies with ≤100 participants, the pooled MD 
13.79 pg/mL (95%CI: 8.24, 19.35; p < 0.00001). Thus, plasma TNF-α levels were 1.7 times higher in 
studies with more than 100 participants, compared to plasma TNF-α levels in studies with ≤100 
participants. 
3.8.3. Mean AHI of Participants with OSAS 
For serum TNF-α levels, the pooled MD for studies including participants with OSAS and an 
AHI > 30 events/h was 12.94 pg/mL (95% CI: 7.74, 18.13; p < 0.00001); the pooled MD for studies 
including participants with OSAS and an AHI ≤ 30 events/h was 173.00 pg/mL (95%CI: 139.66, 
206.34; p < 0.00001). Thus, serum TNF-α levels were 13.4 times higher in participants with OSAS 
and AHI ≤ 30 events/h, compared to the serum TNF-α levels in participants with OSAS and AHI > 
30 events/h. 
For plasma TNF-α levels, the pooled MD for studies including participants with OSAS and an 
AHI > 30 events/h was 16.13 pg/mL (95% CI: 11.20, 21.06; p < 0.00001). When studies included 
participants with OSAS had an AHI ≤ 30 events/h, MDs between studies including participants 
with or without OSAS were not significant. 
3.9. Meta-Regression 
The results of meta-regression showed that age, the publication year, the mean BMI, the mean 
AHI, and the number of participants did not systematically change serum and plasma TNF-α levels 
(Table 7). 
Table 7. Meta-regression analysis based on some variables for serum and plasma levels of tumor 
necrosis factor alpha in obstructive sleep apnea syndrome patients compared with controls in adult 
participants. 
Year of 
Publication 
R 
Adjusted 
R2 
p 
Mean 
Age of 
OSAS 
Patients 
R 
Adjusted 
R2 
p 
Mean 
Age of 
Controls 
R 
Adjusted 
R2 
p 
Serum  0.014 −0.036 0.942 Serum  0.111 −0.024 0.567 Serum  0.081 −0.030 0.678 
Plasma 0.384 0.091 0.128 Plasma 0.018 −0.066 0.946 Plasma 0.079 −0.060 0.764 
Mean BMI 
of OSAS 
patients 
R 
Adjusted 
R2 
p 
Mean 
BMI of 
controls 
R 
Adjusted 
R2 
p 
Mean 
AHI of 
OSAS 
patients 
R 
Adjusted 
R2 
p 
Serum  0.122 −0.025 0.545 Serum  0.159 −0.014 0.429 Serum  0.339 0.075 0.105 
Plasma 0.201 −0.024 0.439 Plasma 0.292 0.024 0.256 Plasma 0.126 −0.054 0.641 
Number of 
participants 
R 
Adjusted 
R2 
p         
Serum  0.004 −0.36 0.985         
Plasma 0.202 −0.023 0.438         
BMI, Body mass index; OSAS, Obstructive sleep apnea syndrome. R: Correlation coefficient. 
3.10. Quality Assessment 
The quality score of each study included in the meta-analysis is illustrated in Table 8. 
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Table 8. Quality assessment scores of the studies involved in the meta-analysis. 
The First Author, Year Selection Comparability Exposure 
Total 
Points 
ADULTS 
Vgontzas, 1997 [28] *** - *** 6 
Huiguo, 2000 [29] *** ** *** 8 
Vgontzas, 2000 [30] *** ** *** 8 
Ciftci, 2004 [31] *** ** *** 8 
Imagawa, 2004 [32] *** * *** 7 
Minoguchi, 2004 [16] *** ** *** 8 
Tazaki, 2004 [33] *** ** *** 8 
Ryan, 2005 [34] *** ** *** 8 
Kobayashi, 2006 [35] *** ** *** 8 
Ryan, 2006 [36] *** ** *** 8 
de la Peña Bravo, 2007 [38] *** ** *** 8 
Arias, 2008 [39] *** ** *** 8 
Constantinidis, 2008 [40] *** ** *** 8 
Kanbay, 2008 [41] *** ** *** 8 
Tomiyama, 2008 [43] *** ** *** 8 
Carneiro, 2009 [44] *** * *** 7 
Li, 2009 [45] *** ** *** 8 
Thomopoulos, 2009 [46] *** ** *** 8 
Sahlman, 2010 [47] *** ** *** 8 
Steiropoulos, 2010 [48] *** ** *** 8 
Sarac, 2011 [49] *** * *** 7 
Fornadi, 2012 [50] *** ** *** 8 
Medeiros, 2012 [51] *** ** *** 8 
Qian, 2012 [52] *** ** *** 8 
Chen, 2013 [54] *** * *** 7 
Hargens, 2013 [56] *** ** *** 8 
Matos, 2013 [57] *** ** *** 8 
Yang, 2013 [58] *** ** *** 8 
Ciccone, 2014 [59] *** ** *** 8 
Sun, 2014 [60] *** ** *** 8 
Unuvar Dogan, 2014 [61] *** ** *** 8 
Chen, 2015 [62] *** ** *** 8 
De, 2015 [63] *** ** *** 8 
Jiang, 2015 [64] *** ** *** 8 
Thunström, 2015 [65] **** ** *** 9 
Lin, 2016 [67] *** ** *** 8 
Nizam, 2016 [68] *** ** *** 8 
Vicente, 2016 [69] *** ** *** 8 
Hirotsu, 2017 [70] **** ** *** 9 
Jiang, 2017 [71] *** * *** 7 
Jin, 2017 [72] *** ** *** 8 
Bozic, 2018 [75] *** ** *** 8 
Kong, 2018 [76] *** ** *** 8 
Ming, 2019 [78] *** * *** 7 
Tang, 2019 [79] *** ** *** 8 
Galati, 2020 [80] **** ** *** 9 
Children 
Tam, 2006 [37] **** ** *** 9 
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Li, 2008 [42] *** * *** 7 
Alexopoulos, 2013 [53] *** * *** 7 
Chu, 2013 [55] *** - *** 6 
Gaines, 2016 [66] *** * *** 7 
Huang, 2016 [14] *** * *** 7 
Smith, 2017 [73] *** * *** 7 
Zhang, 2017 [74] *** * *** 7 
Rogers, 2018 [77] *** * *** 7 
Each asterisk (*) denotes 1 point. 
3.11. Sensitivity Analysis 
The “cumulative analysis” and the “one study removed” as two sensitivity analyses showed 
the stability of the results. In addition, excluding statistically the studies with outliers data did not 
change pooled analysis of serum (MD = 4.53 pg/mL, p < 0.00001) and plasma (MD = 4.18 pg/mL, p < 
0.00001) TNF-α levels (Table 9). 
Table 9. Sensitivity analysis on the results of serum and plasma levels in adults participants. 
First Author, Year Sample Reason for Removing MD (95%CI) Z p-Value I2 Ph 
Jiang, 2015 [64] Serum Outlier data 4.53 (3.48, 5.57) 8.87 <0.00001 100 <0.00001 
Huiguo, 2000 [29] Plasma Outlier data 4.18 (2.58, 5.78) 5.11 <0.00001 99 <0.00001 
CI, Confidence interval; MD, Mean difference; Ph, Pheterogeneity. 
3.12. Publication Bias 
Figure 6 shows the funnel plots of the analysis of serum and plasma TNF-α levels and Table 10 
illustrates the results of trim-and-fill method on bias. 
Table 10. The results of trim-and-fill method. 
Sample Value 
Studies 
Trimmed 
Fixed-Effects Random-Effects 
Q Value Point 
Estimate 
Lower 
Limit 
Upper 
Limit 
Point 
Estimate 
Lower 
Limit 
Upper 
Limit 
Serum 
Observed - 0.40992 0.36474 0.45509 8.24489 7.00639 9.48339 8710.33950 
Adjusted 15 0.32271 0.27770 0.36771 0.52315 −0.88882 1.93512 17050.9022 
Plasma 
Observed - 2.46259 2.32314 2.60204 5.45206 3.50092 7.40320 2508.21501 
Adjusted 3 2.29455 2.15605 2.43306 2.66813 0.63833 4.69794 3161.99635 
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Figure 6. Funnel plot of analysis of tumor necrosis factor alpha levels in adult participants on (A) 
serum and (B) plasma in adult participants. Open circles represent observed studies. Black circles 
represent imputed studies. Open diamond represents the pooled effects from the original studies. 
Black diamond represents the pooled effects incorporating the imputed studies. 
For serum levels, Egger’s and Begg’s tests (p = 0.02431 and p = 0.04677, respectively) revealed a 
publication bias. For plasma TNF-α levels, Begg’s test (p = 0.03943) revealed a publication bias, but 
Egger’s test (p = 0.19315) did not show any bias between and across the studies. 
For serum TNF-α levels and 15 imputed studies, under the fixed-effects model, the point 
estimate and pseudo 95% CI for the combined studies was 0.410 (0.365, 0.455); using the trim-fill 
method, the imputed point estimate was 0.323 (0.278, 0.368). In addition, under the random-effects 
model, the point estimate and 95% CI for the combined studies was 8.245 (7.006, 9.483); using the 
trim-fill method, the imputed point estimate was 0.523 (−0.889, 1.935). 
For plasma TNF-α levels and 3 imputed studies, under the fixed-effects model, the point 
estimate and 95% CI for the combined studies was 2.463 (2.323, 2.602), and using trim-fill method, 
the imputed point estimate was 2.294 (2.156, 2.433). In addition, under the random-effects model, 
the point estimate and pseudo 95% CI for the combined studies was 5.452 (3.501, 7.403); using the 
trim-fill method, the imputed point estimate was 2.668 (0.638, 4.698). 
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The overall effect sizes on serum and plasma TNF-α levels reported in the forest plot appeared 
valid, with trivial publication bias effect based on fixed-effects model, because the observed 
estimates were similar to the adjusted estimates. In contrast, the overall effect sizes on serum and 
plasma TNF-α levels reported in the forest plot appeared invalid, with significant publication bias 
effect based on random-effects model, because the observed estimates had high difference with the 
adjusted estimates. 
4. Discussion 
The present meta-analysis with 55 studies evaluated the serum TNF-α levels (29 studies of 
adults and 4 studies of children) and plasma TNF-α levels (17 studies of adults and 5 studies of 
children) in individuals with OSAS, compared to controls. The results showed that plasma and 
serum TNF-α levels in adult individuals with OSAS were significantly higher than the 
corresponding levels of control. For children with OSAS serum TNF-α levels, but not plasma TNF-α 
levels, were statistically significantly higher than those of controls. The present results have clinical 
importance because elevated serum and plasma TNF-α levels can be a risk factor for the 
development of further systemic diseases in adults with OSAS. Further, more generally, 
inflammation may play a crucial role in the pathogenesis of OSAS, and there is evidence that 
individuals with OSAS have elevated interleukin TNF-α [16,29,40,41,45,48,62,78]. These conclusions 
also have practical importance because, in addition to routine checks on sleep and sleep-disordered 
breathing, both children and adults with OSAS need a thorough monitoring of their immune 
systems. 
Elevated TNF-α levels have been associated with the pathophysiology of reoxygenation injury, 
myocarditis, cardiac allograft vasculopathy, heart failure progression [81], arthritis, diabetes, 
Crohn’s disease, and also cachexia which correlated with terminal malignancy and AIDS [82]. 
Further, TNF-α is a well-known inflammatory marker, besides being related to atherosclerosis in 
males [83]. It is also confirmed that hypoxia raises the expression of proinflammatory molecules 
such TNF-α [84,85]. 
The present pattern of results also sheds some light on further new findings: More specifically, 
for adults, it turned out that compared to healthy controls, TNF-α levels were higher both in blood 
serum and blood plasma. It follows that at least for adults with OSAS, assessing either blood 
plasma or blood serum does not appear to be of clinical importance. In contrast, for pediatric 
samples and compared to healthy controls, higher TNF-α levels were observed for blood serum but 
not for blood plasma. The quality of the data at hand does not allow a deeper understanding of the 
underlying physiological mechanisms. Thus, for want of such data, the following admittedly 
speculative assumptions are advanced. First, it is conceivable that for pediatric samples, the number 
of four studies on plasma TNF-α was too small, and therefore, the statistical variance of plasma 
TNF-α was blurred by sample size inconsistencies. Similarly, second, at least among adults, Hirotsu 
et al. (70) showed that OSAS and inflammatory markers such as IL-6 and TNF-α were associated 
with gender in a very complex fashion. A closer inspection of the four studies on plasma TNF-α 
among pediatric samples showed that gender was not introduced as a specific factor or confounder. 
Given this lack of analyses in these publications, possible gender effects could neither be confirmed, 
nor declined. Third, Imani et al. [86] showed that for pediatric samples, the definition of OSAS was 
not applied as strict and consistent as among adult samples. It follows that the zero-differences of 
plasma TNF-α between children with and without OSAS might mirror inconsistencies as regards 
the definition of control samples. Fourth, Cameron et al. [87] observed that besides the disease 
status, in pediatric samples with Inflammatory Bowel Disease, the outcome of an antitumor 
necrosis factor (TNF) therapy depended from participants’ pubertal stage. Given this, it is 
conceivable that the zero-difference of plasma TNF-α between pediatric samples with and without 
OSAS might have been blurred by the pubertal stage. In the same vein, fifth, it is conceivable that 
pubertal stage and its implicit growth spurt in height and weight might have obscured a clear-cut 
pattern of results as regards TNF-α levels between children with and without OSAS. Last, even if 
highly unlikely, one cannot rule out that the pattern of results is an accidental finding. 
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The pattern of results described in the present meta-analysis and systematic review 
consistently showed that higher TNF-α levels were associated with pathologically higher BMI 
scores as a proxy of obesity. Given that above all childhood overweight and childhood obesity is 
increasing worldwide and is a major concern of public health [88], the association between 
overweight/obesity, TNF-α levels and OSAS demand particular attention. Following Popa et al. 
[13], TNF-alpha appeared to be of upmost importance in the development and maintenance of 
metabolic diseases in which a shift toward a proatherogenic lipid profile and impaired glucose 
tolerance appeared to occur. Further, investigations assessing the impact of anti-TNF agents on 
intermediary metabolism seemed to show that a TNF-alpha blockade may improve insulin 
resistance and lipid profiles, which in turn appeared to be associated with overweight and obesity. 
Likewise, Ciftci et al. [31] showed in their study that compared to obese males with no OSAS, in 
obese males with OSAS TNF-alpha levels were significantly higher. Ciftci et al. [31] concluded from 
their results, that the association between cardiovascular morbidity and OSAS appeared to be best 
described by the coexistence of other cardiovascular risk factors such as circulating IL-6 and TNF-
alpha levels. In the same vein, Sahlman et al. [47] showed in their study that pro-inflammatory 
markers such as TNF-alpha were markedly increased in patients with mild OSAS. To find a 
physiological explanation for such processes, Steiropoulos et al. [48] summarized in their 
introduction that besides the role of energy depot adipose tissue is also an active endocrine organ, 
releasing proinflammatory cytokines such as Tumor Necrosis Factor-α (TNF-α) and Interleukin-6 
(IL-6) which modulate blood pressure, and lipid- and glucose-metabolism. Further, the 
proinflammatory transcription factor NF-κB appears to be upregulated in OSAS as a result of 
alterations between hypoxia and reoxygenation and as a result of sleep deprivation. Additionally, 
NF-κB regulates the expression of inflammatory genes. Given these physiological processes, it 
appears plausible that OSAS, obesity and poor sleep appear to be highly interrelated. 
The results of one study [70] showed that IL-6, triglycerides, and AHI were positively 
associated with TNF-α, while sex, ghrelin and total cholesterol had a negative association. Further, 
postmenopausal women had higher TNF-α levels than those of premenopausal women [70]. One 
study showed that higher TNF-α levels were significantly related to some neurocognitive deficits in 
children with OSAS [14]. 
Next, TNF-α appears to mediate both a somnogenic activity and fatigue related to excessive 
daytime somnolence in obese patients with OSAS [14,28,30]. TNF-α levels were related to the 
severity of OSAS [31]. One study reported that BMI was weakly related to TNF-α levels [32]. 
However, Kanbay et al. [41] showed that in individuals with OSAS and obesity serum TNF-α levels 
were significantly higher than those without obesity. Not surprisingly, there was also a positive 
albeit modest correlation (r: 0.181; p: 0.034) between higher BMI scores and higher TNF-α levels 
[16]. 
As regards AHI and TNF-α levels, Kanbay et al. [41] and others [16,78] reported a significant 
positive correlation between a higher AHI and higher serum TNF-α levels. 
Next, Minoguchi et al. [16] reported in their meta-analysis higher plasma and serum TNF-α 
levels in adults, compared to non-adults. 
Despite the novelty of the results, the following limitations should be considered: (1) In all 
studies, results have not been adjusted for possible confounding factors such as obesity, smoking, 
or alcohol consumption. (2) The results of the funnel plots showed a publication bias across the 
studies; it follows that a systematic bias in the data presentation cannot be ruled out. (3) Studies 
with a small sample size (less than100 cases) had an inadequate power to detect possibly 
meaningful associations. (4) There was a high heterogeneity among studies in some analyses. (5) 
Studies reported different cut-off AHI values, which made comparisons between the studies 
difficult. (6) In some studies, TNF-α levels were considered as secondary outcome. (7) In some 
studies, the existence of mixed ethnicities might have blurred the associations between the ethnicity 
and TNF-α levels. 
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By contrast, the strengths of the meta-analysis were as follows: (1) There were sufficient studies 
to allow the subgroup analyses. (2) The sensitivity analysis showed a stability of the results. (3) The 
studies written in other languages than English were included in the meta-analysis. 
5. Conclusions 
The result of the meta-analysis and meta-regression confirmed that compared to healthy 
controls, individuals with OSAS (adults) had significant higher serum/plasma TNF-α levels, 
whereas for children with OSAS, this pattern of results was observed for serum TNF-α levels, but 
not for plasma TNF-α levels. Last, the results of the present meta-analysis showed that elevated 
TNF-α levels in individuals with OSAS appeared to be related to the severity of the disease. Future 
studies might investigate if and to what extent interventions on OSAS (e.g., using CPAP devices) 
favorably impact on TNF-α levels and possibly also on weight regulation. 
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